OptiNose (NASDAQ:OPTN) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of OptiNose (NASDAQ:OPTN) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. Lake Street Capital cut shares of OptiNose from a “buy” rating to a “hold” rating and decreased their target price for the company from $17.00 to $9.00 in a research report on Thursday, March 20th. Piper Sandler reaffirmed a “neutral” rating and set a $9.00 price target (down from $15.00) on shares of OptiNose in a research report on Friday, March 21st.

OptiNose Trading Up 0.2%

Shares of NASDAQ OPTN opened at $9.71 on Monday. OptiNose has a 12-month low of $4.82 and a 12-month high of $20.03. The stock’s fifty day simple moving average is $8.89 and its two-hundred day simple moving average is $7.42. The stock has a market capitalization of $98.33 million, a PE ratio of -2.31 and a beta of -0.88.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.27). The company had revenue of $18.51 million during the quarter, compared to analysts’ expectations of $17.70 million. On average, equities analysts predict that OptiNose will post -3.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the sale, the chief executive officer now directly owns 126,931 shares of the company’s stock, valued at $671,464.99. The trade was a 4.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 8,213 shares of company stock valued at $43,643. 2.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On OptiNose

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPTN. PenderFund Capital Management Ltd. acquired a new position in shares of OptiNose in the first quarter valued at about $172,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in OptiNose in the first quarter valued at approximately $558,000. Gabelli Funds LLC acquired a new position in OptiNose in the 1st quarter worth approximately $734,000. Stonepine Capital Management LLC raised its position in OptiNose by 34.0% during the 1st quarter. Stonepine Capital Management LLC now owns 788,647 shares of the company’s stock worth $7,232,000 after buying an additional 199,990 shares during the last quarter. Finally, Groupe la Francaise acquired a new stake in OptiNose during the 1st quarter valued at approximately $1,898,000. Hedge funds and other institutional investors own 85.60% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.